Adverum Biotechnologies Provides Clinical Program Update on ADVM-022 Gene Therapy for Wet AMD
Adverum Biotechnologies, Inc. (ADVM)
Last adverum biotechnologies, inc. earnings: 3/12 04:01 pm
Check Earnings Report
US:NASDAQ Investor Relations:
adverum.gcs-web.com/investor-overview
Company Research
Source: GlobeNewswire
- Clinical Hold until Additional CMC Information is Reviewed by FDA -- Independent DMC Review of Safety Data from First Cohort of Six Patients with No SAEs or DLTs -- Adverum Plans to Present 24-Week Data from First Cohort of Patients at Scientific Meeting in 2H19 - MENLO PARK, Calif., April 15, 2019 (GLOBE NEWSWIRE) -- Adverum Biotechnologies, Inc. (Nasdaq: ADVM), a clinical-stage gene therapy company targeting unmet medical needs in ocular and rare diseases, today provided a program update on ADVM-022, a novel, single-administration gene therapy being evaluated in the OPTIC Phase 1 clinical trial in patients with wet age-related macular degeneration (wet AMD). The Company has completed enrollment and dosing of patients (n=6) in the first cohort in the OPTIC trial. The independent data monitoring committee (DMC) determined that enrollment and dosing of patients in the second cohort could proceed. This was based on a review of the preliminary safety data from the first coh
Show less
Read more
Impact Snapshot
Event Time:
ADVM
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
ADVM alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
ADVM alerts
High impacting Adverum Biotechnologies, Inc. news events
Weekly update
A roundup of the hottest topics
ADVM
News
- Has Adverum Biotechnologies (ADVM) Outpaced Other Medical Stocks This Year? [Yahoo! Finance]Yahoo! Finance
- Gene Therapies in Ophthalmology Market to Register Immense Growth at a CAGR of 57.8% by 2034 | DelveInsight [Yahoo! Finance]Yahoo! Finance
- Are Medical Stocks Lagging Adverum Biotechnologies (ADVM) This Year? [Yahoo! Finance]Yahoo! Finance
- Down -29.25% in 4 Weeks, Here's Why You Should You Buy the Dip in Adverum Biotechnologies (ADVM) [Yahoo! Finance]Yahoo! Finance
- Adverum Biotechnologies, Inc. (NASDAQ: ADVM) was upgraded by analysts at StockNews.com from a "sell" rating to a "hold" rating.MarketBeat
ADVM
Earnings
- 11/9/23 - Miss
ADVM
Sec Filings
- 4/1/24 - Form EFFECT
- 3/27/24 - Form EFFECT
- 3/21/24 - Form S-3
- ADVM's page on the SEC website